Avastin advertising contracted before FDA decision

12/13/2011 | Medical Marketing & Media

Roche's Genentech unit reduced spending on journal ads for Avastin well before the FDA revoked approval for the drug to treat breast cancer. Genentech stopped promoting Avastin for breast cancer in August 2010 and reduced spending on journal ads for other indications in 2011, a spokeswoman said.

View Full Article in:

Medical Marketing & Media

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR